drugset / Trial / NCT05007769
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
Phase 2
Withdrawn
Washington University School of Medicine
Eli Lilly and Company · collabImmunityBio, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that the addition of ramucirumab and N-803 will augment the clinical activity of atezolizumab, and in order to evaluate the exact mechanism of action of the combination, the investigators propose a comprehensive analysis of paired peripheral blood samples collected during this study.
Timeline
- Start
- 2021-10-31
- Primary completion
- 2024-04-30
- Completion
- 2026-04-30
Outcome
Outcome not reported
Stopped (Business): “Lost funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Ramucirumab | Monoclonal antibody | — | Intravenous |